Solid Biosciences Reports Encouraging Phase 1/2 Duchenne Data

Solid Biosciences ( (SLDB) ) has shared an announcement.

On March 11, 2026, Solid Biosciences reported positive interim data from its first-in-human Phase 1/2 INSPIRE DUCHENNE trial of SGT-003 in 40 pediatric patients with Duchenne muscular dystrophy, based on a February 23, 2026 data cutoff. The treatment was generally well tolerated under a steroid-only immunomodulation regimen across 15 sites in the U.S., Canada, Italy and the U.K., with dosing continuing.

Biopsies from 20 participants at Day 90 and three at Day 360 showed robust microdystrophin transduction and expression, along with restored beta-sarcoglycan and nNOS activity, suggesting reconstitution of critical components of the dystrophin-associated protein complex. A marked reduction in embryonic myosin heavy chain-positive fibers and decreases in multiple serum muscle damage biomarkers indicated improved muscle integrity and potential interruption of the chronic degeneration-regeneration cycle.

Cardiac assessments, initially planned for safety, showed stabilization to improvement in left ventricular ejection fraction, particularly in participants who began with low-normal systolic function, addressing a key cause of morbidity and mortality in Duchenne. Solid Biosciences also confirmed it has reached agreement with the U.S. Food and Drug Administration on the design of its Phase 3 IMPACT DUCHENNE trial of SGT-003, with screening underway and first dosing expected in the first quarter of 2026, underscoring a clear regulatory and clinical path that could strengthen the company’s position in the competitive Duchenne gene therapy landscape.

The most recent analyst rating on (SLDB) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on Solid Biosciences stock, see the SLDB Stock Forecast page.

Spark’s Take on SLDB Stock

According to Spark, TipRanks’ AI Analyst, SLDB is a Neutral.

The score is held down primarily by very weak fundamentals—zero TTM revenue, widening losses, and significant ongoing cash burn—despite a relatively low-debt balance sheet. Technicals are moderately supportive with neutral-to-positive momentum, but valuation remains difficult to justify on earnings due to the negative P/E and no dividend.

To see Spark’s full report on SLDB stock, click here.

More about Solid Biosciences

Solid Biosciences Inc. is a biotechnology company focused on developing gene therapies for Duchenne muscular dystrophy, a rare, progressive neuromuscular disease affecting children. Its lead investigational product, SGT-003, is a microdystrophin gene therapy administered as a one-time intravenous infusion, targeting restoration of key dystrophin-associated protein complex functions in pediatric patients.

Average Trading Volume: 1,273,833

Technical Sentiment Signal: Buy

Current Market Cap: $601.1M

For detailed information about SLDB stock, go to TipRanks’ Stock Analysis page.